8k out
Form 8-K for CELL THERAPEUTICS INC
9-Feb-2010
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Item 7.01 Regulation FD Disclosure.
A copy of the Cell Therapeutics, Inc.'s (the "Company") press release, entitled "FDA Postpones Oncologic Drugs Advisory Committee Meeting to Review Pixantrone Due to Severe Weather Conditions" is furnished and not filed pursuant to Item 7.01 as Exhibit 99.1 hereto. Such information shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.
Item 8.01 Other Events.
On February 9, 2010, the Company announced that the U.S. Food and Drug Administration (the "FDA") informed the Company that due to severe weather conditions in the Washington, D.C. area, the FDA postponed the Oncologic Drugs Advisory Committee meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application. The FDA indicated that it intends to reschedule the meeting as soon as the FDA can determine a schedule that will allow them to reconvene the advisory panel.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number Description
99.1 Press Release, dated February 9, 2010, entitled "FDA Postpones Oncologic
Drugs Advisory Committee Meeting to Review Pixantrone Due to Severe
Weather Conditions."
AI
